A revised industry analysis on the osteoporosis drugs market by Persistence Market Research provides a detailed account of the landscape and predicts suitable forecasts.
From 2016 to 2020, the global osteoporosis drugs market exhibited a CAGR of 2.6%, and is expected to increase 1.3X over the forecast of 2021-2031. By the end of the decade, the industry is expected to be valued at approximately US$ 18 Bn. The North American market is valued at around US$ 4 Bn and holds 2/5 of the global market share.
Find Out More about the Report Coverage
- Eli Lilly and Company
- F. Hoffmann-La Roche Ltd.
- Merck & Co, Inc.
- Novartis AG
- Amgen, Inc.
- Novo Nordisk A/S
- Actavis plc
- Pfizer, Inc.
- GlaxoSmithKline plc
- Teva Pharmaceutical Industries Ltd
Key Market Insights Provided in Osteoporosis Drugs Industry Survey:
- Market estimates and forecast 2016-2031
- Key drivers and restraints impacting market growth
- Segment-wise, country-wise, and region-wise analysis
- Competition mapping and benchmarking
- Brand share and market share analysis
- Key product innovations and regulatory climate
- COVID-19 Impact on sales of osteoporosis drugs and how to navigate
- Recommendation on key winning strategies
Customize this Report
Explore Intelligence Tailored to Your Business Goals.
Research and Developments in Osteoporosis
Osteoporosis has become a common issue in recent times, and cases are rising as lifestyles become increasingly sedentary. As osteoporosis becomes a common issue, research & development for treatment drugs for this condition has also increased.
To make a stabilized human calcitonin, Purdue University created a prodrug form of the peptide hormone and increased its effectiveness as an osteoporosis treatment. Through this, researchers have improved the therapeutic benefits of human calcitonin.
Entera Bio recently announced some positive results from a bone mineral density study that it was conducting, which was in its second phase. EB613 is an oral formulation of human parathyroid hormone (1-34), which is expected to be the first oral bone building (anabolic) product to treat osteoporosis patients.
After the positive results of the 6-month long phase two study in 161 postmenopausal female subjects with osteoporosis, the study is expected to gain further impetus and develop a new breakthrough in the osteoporosis drugs industry.
Market Research Methodology - Perfected through Years of Diligence
A key factor for our unrivaled market research accuracy is our expert- and data-driven research methodologies. We combine an eclectic mix of experience, analytics, machine learning, and data science to develop research methodologies that result in a multi-dimensional, yet realistic analysis of a market.
The global osteoporosis drugs market is projected to exhibit sluggish growth by the end of 2031 with escalating demand for these drugs across the globe for the treatment of ailments such as prophylaxis. The wide range of pipeline drugs are expected to create new revenue prospects in the market.
Growing osteoporosis conditions bred by the sedentary lifestyle is expected to drive the adoption rate of these drugs in the coming years.
Explore Persistence Market Research’s expertise in promulgation of the business !
Effect of COVID-19
The COVID-19 pandemic is expected to reduce demand for a brief time period owing to reduction in reported cases of ailments. The market is expected to witness a surge in demand with growing relaxations in people's movements.
North America is projected to hold major market share by the end of the forecast period owing to enhanced research & development activities and high medical standards.
Burgeoning investments are expected to impart a high growth rate to the osteoporosis market in the Asia Pacific, creating new revenue pockets to the manufacturers.
The market players are adopting collaborative strategies to sustain market competition. The manufactures are investing in research and development to introduce innovative products in the market. Established players in the market include Novo Nordisk A/S, GlaxoSmithKline plc, F. Hoffmann-La Roche Ltd., Pfizer, Inc., and Novartis AG.
The global osteoporosis drugs market is witnessing significant growth due to rising geriatric population and changing lifestyles impinging bone health. Moreover, increasing the prevalence of osteoporosis in postmenopausal women, growing awareness about osteoporotic care, and increasing investment in drug discovery and development are also driving the growth of the market.
However, there are various side effects and complications associated with osteoporosis drugs such as heartburn, irritable bowel syndrome, nausea, and ulcers in the stomach or esophagus. Furthermore, patent expiration of osteoporosis drugs also inhibits growth of the market.
The osteoporosis drugs market is anticipated to grow from an estimated US$ 12.5 Bn in 2021 to account for US$ 18 Bn by 2031, at a CAGR of 3.8%. North America is the largest market for osteoporosis drugs, with bisphosphonates being the most popular type of osteoporosis drugs. Asia-Pacific is the fastest growing region in terms of revenue while RANK ligand inhibitors are the fastest growing type of osteoporosis drugs.
This report provides in-depth analysis and estimation of the osteoporosis drugs market for 2021– 2031, considering 2020 as the base year for calculation. Moreover, data pertaining to current market dynamics, including market drivers, restraints, trends, and recent developments, has been provided in the report.
FAQs Answered in Market Study
- How much is the osteoporosis drugs market currently worth?
The global osteoporosis drugs market is currently worth around US$ 12.5 Bn.
- What valuation will the osteoporosis drugs industry hit by the end of the decade?
Sales of osteoporosis drugs are anticipated to attain a valuation of nearly US$ 18 Bn by 2031.
- At what pace did the market evolve in the past 5 years?
The osteoporosis drugs industry progressed at a very slow CAGR of 2.6% in the past 5 years.
- What does the market share of the top 5 manufacturers of osteoporosis drugs amount to?
Top 5 players in the market collectively account for approximately 45% of the global market share.
- What CAGR is expected for the forecast period?
The osteoporosis drugs market is expected to exhibit a steady CAGR of 3.8% from 2021 to 2031.
- What are the market metrics for South Korea and Japan?
The osteoporosis drugs market in Japan is estimated to expand at a CAGR of 2.2%, and South Korea at 4.2%.
- What are the key trends propelling demand for osteoporosis drugs?
Adoption of patient-centric strategies in drug development, and as key drugs approach the expiration of their patents, manufacturers are eying more clinical developments and new opportunities.
- Which factors are influencing the osteoporosis drugs market outlook?
Increasing instances of fractures in the geriatric population, osteoporotic fractures in women caused by early menopause due to sedentary lifestyle, and increasing screening and public awareness programs are major factors directing market growth.
- Which countries are at the forefront in terms of demand for osteoporosis drugs?
The U.S., Japan, Germany, U.K., and China are leading nations in terms of demand for osteoporosis drugs.
- What are the osteoporosis drugs market statistics for the North American region?
New product launches and shift from antiresorptive agents to anabolic therapies are expected to influence the North American market majorly, which will hold 40% of the global market share.
- What is expansion rate in the European region for osteoporosis drugs?
The market in Germany is expected to progress at a CAGR of 3.1%, Italy at 4.1%, France at 3.8%, the U.K. at 4.2%, and Spain at 3.3%.